Literature DB >> 9044487

Pulmonary sarcoid-like granulomata in a patient treated for extrapulmonary Hodgkin's disease.

M Fickers, P Theunissen, J A van Noord.   

Abstract

We report a case of interstitial lung disease developing during treatment with chlorambucil, vinblastine, procarbazine and prednisone for extrapulmonary Hodgkin's disease. Transbronchial biopsies demonstrated noncaseating epithelioid cell granulomata, and bronchoalveolar lavage fluid showed an increased percentage of lymphocytes, with a raised T cell helper-suppressor ratio, suggesting a diagnosis of sarcoidosis. Treatment with corticosteroids brought about complete resolution of the radiographic lesions. A possible relationship between sarcoidosis and lymphoma is discussed, and a short review of the literature is given. This case report has some unique features that, to our knowledge, have not been published before.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9044487     DOI: 10.1159/000196654

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  3 in total

1.  Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report.

Authors:  Vivek Subbiah; Uyen K Ly; Amer Khiyami; Timothy O'Brien
Journal:  J Med Case Rep       Date:  2007-11-25

Review 2.  A case of resectable lung adenocarcinoma associated with sarcoidosis.

Authors:  H Yanagawa; H Goto; K Maniwa; F Ogushi; K Takahashi; Y Monden; T Hirose; N Sano; S Sone
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

Review 3.  Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature.

Authors:  Jonathan London; Aurélie Grados; Christophe Fermé; Alexandre Charmillon; François Maurier; Bénédicte Deau; Etienne Crickx; Pauline Brice; Catherine Chapelon-Abric; Corinne Haioun; Barbara Burroni; Marco Alifano; Claire Le Jeunne; Loïc Guillevin; Nathalie Costedoat-Chalumeau; Nicolas Schleinitz; Luc Mouthon; Benjamin Terrier
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.